Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

PHD-2 Suppression in Mesenchymal Stromal Cells Enhances Wound Healing.

Ko SH, Nauta AC, Morrison SD, Hu MS, Zimmermann AS, Chung MT, Glotzbach JP, Wong VW, Walmsley GG, Peter Lorenz H, Chan DA, Gurtner GC, Giaccia AJ, Longaker MT.

Plast Reconstr Surg. 2018 Jan;141(1):55e-67e. doi: 10.1097/PRS.0000000000003959.

2.

Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells.

Padró M, Louie RJ, Lananna BV, Krieg AJ, Timmerman LA, Chan DA.

BMC Cancer. 2017 Mar 20;17(1):203. doi: 10.1186/s12885-017-3140-9.

3.

ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth.

Humtsoe JO, Pham E, Louie RJ, Chan DA, Kramer RH.

Oncogene. 2016 Mar 24;35(12):1554-64. doi: 10.1038/onc.2015.220. Epub 2015 Jun 15.

PMID:
26073080
4.

Numerical chromosomal instability mediates susceptibility to radiation treatment.

Bakhoum SF, Kabeche L, Wood MD, Laucius CD, Qu D, Laughney AM, Reynolds GE, Louie RJ, Phillips J, Chan DA, Zaki BI, Murnane JP, Petritsch C, Compton DA.

Nat Commun. 2015 Jan 21;6:5990. doi: 10.1038/ncomms6990.

5.

Epidermal or dermal specific knockout of PHD-2 enhances wound healing and minimizes ischemic injury.

Zimmermann AS, Morrison SD, Hu MS, Li S, Nauta A, Sorkin M, Meyer NP, Walmsley GG, Maan ZN, Chan DA, Gurtner GC, Giaccia AJ, Longaker MT.

PLoS One. 2014 Apr 2;9(4):e93373. doi: 10.1371/journal.pone.0093373. eCollection 2014.

6.

Identifying novel targets in renal cell carcinoma: design and synthesis of affinity chromatography reagents.

Bonnet M, Flanagan JU, Chan DA, Giaccia AJ, Hay MP.

Bioorg Med Chem. 2014 Jan 15;22(2):711-20. doi: 10.1016/j.bmc.2013.12.028. Epub 2013 Dec 20.

7.

Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.

Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, Hu M, Chan DA, Ethier SP, van 't Veer LJ, Polyak K, McCormick F, Gray JW.

Cancer Cell. 2013 Oct 14;24(4):450-65. doi: 10.1016/j.ccr.2013.08.020. Epub 2013 Oct 3.

8.

Radiosensitization of renal cell carcinoma in vitro through the induction of autophagy.

Anbalagan S, Pires IM, Blick C, Hill MA, Ferguson DJ, Chan DA, Hammond EM.

Radiother Oncol. 2012 Jun;103(3):388-93. doi: 10.1016/j.radonc.2012.04.001. Epub 2012 Apr 30.

PMID:
22551566
9.

Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality.

Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, Reynolds GE, Chi JT, Wu J, Solow-Cordero DE, Bonnet M, Flanagan JU, Bouley DM, Graves EE, Denny WA, Hay MP, Giaccia AJ.

Sci Transl Med. 2011 Aug 3;3(94):94ra70. doi: 10.1126/scitranslmed.3002394.

10.

SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells.

Bonnet M, Flanagan JU, Chan DA, Lai EW, Nguyen P, Giaccia AJ, Hay MP.

Bioorg Med Chem. 2011 Jun 1;19(11):3347-56. doi: 10.1016/j.bmc.2011.04.042. Epub 2011 Apr 24.

11.

Harnessing synthetic lethal interactions in anticancer drug discovery.

Chan DA, Giaccia AJ.

Nat Rev Drug Discov. 2011 May;10(5):351-64. doi: 10.1038/nrd3374. Review.

12.

Hypoxia-inducible factor-1 activation in nonhypoxic conditions: the essential role of mitochondrial-derived reactive oxygen species.

Patten DA, Lafleur VN, Robitaille GA, Chan DA, Giaccia AJ, Richard DE.

Mol Biol Cell. 2010 Sep 15;21(18):3247-57. doi: 10.1091/mbc.E10-01-0025. Epub 2010 Jul 21.

13.

Toxoplasma gondii activates hypoxia-inducible factor (HIF) by stabilizing the HIF-1alpha subunit via type I activin-like receptor kinase receptor signaling.

Wiley M, Sweeney KR, Chan DA, Brown KM, McMurtrey C, Howard EW, Giaccia AJ, Blader IJ.

J Biol Chem. 2010 Aug 27;285(35):26852-60. doi: 10.1074/jbc.M110.147041. Epub 2010 Jun 25.

14.

PHD2 in tumour angiogenesis.

Chan DA, Giaccia AJ.

Br J Cancer. 2010 Jun 29;103(1):1-5. doi: 10.1038/sj.bjc.6605682. Epub 2010 May 11. Review.

15.

4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death.

Hay MP, Turcotte S, Flanagan JU, Bonnet M, Chan DA, Sutphin PD, Nguyen P, Giaccia AJ, Denny WA.

J Med Chem. 2010 Jan 28;53(2):787-97. doi: 10.1021/jm901457w.

16.

Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment.

Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, Giaccia AJ.

Cancer Cell. 2009 Jun 2;15(6):527-38. doi: 10.1016/j.ccr.2009.04.010.

17.

Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells.

Ghosh AK, Shanafelt TD, Cimmino A, Taccioli C, Volinia S, Liu CG, Calin GA, Croce CM, Chan DA, Giaccia AJ, Secreto C, Wellik LE, Lee YK, Mukhopadhyay D, Kay NE.

Blood. 2009 May 28;113(22):5568-74. doi: 10.1182/blood-2008-10-185686. Epub 2009 Mar 31.

18.

Molecular imaging of hypoxia-inducible factor 1 alpha and von Hippel-Lindau interaction in mice.

Choi CY, Chan DA, Paulmurugan R, Sutphin PD, Le QT, Koong AC, Zundel W, Gambhir SS, Giaccia AJ.

Mol Imaging. 2008 May-Jun;7(3):139-46.

19.

Tissue engineering using autologous microcirculatory beds as vascularized bioscaffolds.

Chang EI, Bonillas RG, El-ftesi S, Chang EI, Ceradini DJ, Vial IN, Chan DA, Michaels J 5th, Gurtner GC.

FASEB J. 2009 Mar;23(3):906-15. doi: 10.1096/fj.08-114868. Epub 2008 Nov 10.

20.

Short hairpin RNA interference therapy for ischemic heart disease.

Huang M, Chan DA, Jia F, Xie X, Li Z, Hoyt G, Robbins RC, Chen X, Giaccia AJ, Wu JC.

Circulation. 2008 Sep 30;118(14 Suppl):S226-33. doi: 10.1161/CIRCULATIONAHA.107.760785.

21.

Targeting cancer cells by synthetic lethality: autophagy and VHL in cancer therapeutics.

Chan DA, Giaccia AJ.

Cell Cycle. 2008 Oct;7(19):2987-90. Epub 2008 Oct 12. Review.

PMID:
18818511
22.

A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy.

Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA, Giaccia AJ.

Cancer Cell. 2008 Jul 8;14(1):90-102. doi: 10.1016/j.ccr.2008.06.004.

23.

(2R)-[(4-Biphenylylsulfonyl)amino]-N-hydroxy-3-phenylpropionamide (BiPS), a matrix metalloprotease inhibitor, is a novel and potent activator of hypoxia-inducible factors.

Lauzier MC, Robitaille GA, Chan DA, Giaccia AJ, Richard DE.

Mol Pharmacol. 2008 Jul;74(1):282-8. doi: 10.1124/mol.108.045690. Epub 2008 Apr 18.

24.

Age decreases endothelial progenitor cell recruitment through decreases in hypoxia-inducible factor 1alpha stabilization during ischemia.

Chang EI, Loh SA, Ceradini DJ, Chang EI, Lin SE, Bastidas N, Aarabi S, Chan DA, Freedman ML, Giaccia AJ, Gurtner GC.

Circulation. 2007 Dec 11;116(24):2818-29. Epub 2007 Nov 26.

PMID:
18040029
25.

HIF gene expression in cancer therapy.

Chan DA, Krieg AJ, Turcotte S, Giaccia AJ.

Methods Enzymol. 2007;435:323-45. Review.

PMID:
17998061
26.

Hypoxia-inducible factor-1alpha stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion.

Pagé EL, Chan DA, Giaccia AJ, Levine M, Richard DE.

Mol Biol Cell. 2008 Jan;19(1):86-94. Epub 2007 Oct 17.

27.

HIF-1 regulates hypoxia- and insulin-induced expression of apelin in adipocytes.

Glassford AJ, Yue P, Sheikh AY, Chun HJ, Zarafshar S, Chan DA, Reaven GM, Quertermous T, Tsao PS.

Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1590-6. Epub 2007 Sep 18.

28.

Oxygen sensitivity of reporter genes: implications for preclinical imaging of tumor hypoxia.

Cecic I, Chan DA, Sutphin PD, Ray P, Gambhir SS, Giaccia AJ, Graves EE.

Mol Imaging. 2007 Jul-Aug;6(4):219-28.

PMID:
17711777
29.

Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells.

Sutphin PD, Chan DA, Li JM, Turcotte S, Krieg AJ, Giaccia AJ.

Cancer Res. 2007 Jun 15;67(12):5896-905.

30.

Energy regulation: HIF MXIes it up with the C-MYC powerhouse.

Sutphin PD, Giaccia AJ, Chan DA.

Dev Cell. 2007 Jun;12(6):845-6. Review.

31.

Hypoxia, gene expression, and metastasis.

Chan DA, Giaccia AJ.

Cancer Metastasis Rev. 2007 Jun;26(2):333-9. Review.

PMID:
17458506
32.

Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro.

Pan Y, Mansfield KD, Bertozzi CC, Rudenko V, Chan DA, Giaccia AJ, Simon MC.

Mol Cell Biol. 2007 Feb;27(3):912-25. Epub 2006 Nov 13.

33.

Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha.

Chan DA, Sutphin PD, Yen SE, Giaccia AJ.

Mol Cell Biol. 2005 Aug;25(15):6415-26.

34.

OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha.

Baek JH, Mahon PC, Oh J, Kelly B, Krishnamachary B, Pearson M, Chan DA, Giaccia AJ, Semenza GL.

Mol Cell. 2005 Feb 18;17(4):503-12.

35.

JunD reduces tumor angiogenesis by protecting cells from oxidative stress.

Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, Pouysségur J, Yaniv M, Mechta-Grigoriou F.

Cell. 2004 Sep 17;118(6):781-94.

36.

Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development.

Pfander D, Kobayashi T, Knight MC, Zelzer E, Chan DA, Olsen BR, Giaccia AJ, Johnson RS, Haase VH, Schipani E.

Development. 2004 May;131(10):2497-508.

37.

Distinct aerobic and hypoxic mechanisms of HIF-alpha regulation by CSN5.

Bemis L, Chan DA, Finkielstein CV, Qi L, Sutphin PD, Chen X, Stenmark K, Giaccia AJ, Zundel W.

Genes Dev. 2004 Apr 1;18(7):739-44.

38.

Dead cells don't form tumors: HIF-dependent cytotoxins.

Sutphin PD, Chan DA, Giaccia AJ.

Cell Cycle. 2004 Feb;3(2):160-3. Review.

PMID:
14712081
39.

Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha.

Chan DA, Sutphin PD, Denko NC, Giaccia AJ.

J Biol Chem. 2002 Oct 18;277(42):40112-7. Epub 2002 Aug 16.

40.

Munchausen syndrome by proxy: a review and case study.

Chan DA, Salcedo JR, Atkins DM, Ruley EJ.

J Pediatr Psychol. 1986 Mar;11(1):71-80. No abstract available.

PMID:
3958869
41.

The process of recovery from alcoholism. I. Comparing alcoholic patients and matched community controls.

Moos RH, Finney JW, Chan DA.

J Stud Alcohol. 1981 May;42(5):383-402. No abstract available.

PMID:
7278281
42.

Length of stay and program component effects in the treatment of alcoholism: a comparison of two techniques for process analyses.

Finney JW, Moos RH, Chan DA.

J Consult Clin Psychol. 1981 Feb;49(1):120-31. No abstract available.

PMID:
7217465

Supplemental Content

Support Center